Revance Therapeutics reported $-72723000 in EBIT for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebit Change
Adamas Pharmaceuticals ADMS:US -5636000 3.52M
Aerie Pharmaceuticals AERI:US $ -32374000 873K
ALKERMES ALKS:US -19659000 24.08M
Bristol Myers Squibb BMY:US $ 2985M 18M
Coherus Biosciences CHRS:US $ -32787000 8.62M
Eli Lilly And LLY:US $ 2055.2M 626.8M
Endo International Ordinary Shares ENDP:US $ 207.28M 11.74M
Flexion Therapeutics FLXN:US $ -24158000 7.28M
Gw Pharmaceuticals GWPH:US -21027000 1.78M
Horizon Pharma HZNP:US 345.45M 131.68M
JAZZ PHA JAZZ:US 28.37M 97.96M
Johnson & Johnson JNJ:US $ 7033M 2723M
Merk MRK:US $ 5352M 3083M
Neurocrine Biosciences NBIX:US $ 44.5M 23.3M
Pacira Pharmaceuticals PCRX:US $ 30.72M 4.27M
Procter & Gamble PG:US $ 5023M 1374M
Revance Therapeutics RVNC:US $ -72723000 2.39M
Supernus Pharmaceuticals SUPN:US $ 32.6M 1.51M
Teva Pharmaceutical Industries TEVA:US 806M 23M
Zogenix ZGNX:US $ -53870000 1.56M